The Rise and Fall of “Ozempic Vulva”

A term with a lifespan

Most health scares are hard to measure. This one is not, because you can watch it happen in the search data.

In one month, "Ozempic vulva" was searched roughly 54,900 times in the United States. The next month, about 30,900. The month after, 22,000. Then it fell away to a few hundred a month, where it has stayed. That is our analysis of third-party keyword data, and the shape of it is unmistakable: a spike, a decay, and a long quiet tail.

Between the spike and the tail, a very large number of women typed those two words into a search bar and were frightened by what came back.

This is a piece about what the phrase was built on, and what it cost.

What the labels say, which is nothing

Start where a reporter should start, with the primary document.

The current prescribing information for Wegovy contains no occurrence of the words vaginal, vulvovaginal, candidiasis or genital mycotic infection. Not one¹. The Zepbound label contains none of those terms either².

These are not thin documents. They enumerate belching. They enumerate hair loss, flatulence and dry throat — the last of those in one percent of patients. If a vulvar effect were an observed, drug-attributable finding of any frequency, this is precisely where it would appear.

So the phrase never described a documented effect of the medication. It described a set of experiences women were having during rapid weight loss, given a brand name.

Where the name came from

"Ozempic vulva" arrived in the wake of "Ozempic face" — a coinage that worked because it was true enough, memorable, and slightly cruel. The formula was reusable, and it got reused: Ozempic butt, Ozempic teeth, Ozempic feet. Each is a real-ish observation about what losing weight quickly does to a body, wrapped in a drug's brand name that implies causation the evidence does not carry.

It is a good formula for traffic. Our analysis of what ranks for the term shows the front page held by a plastic surgery association, a large consumer health publisher, and a telehealth company that sells GLP-1 prescriptions — alongside, at the very top, a single physician's practice website. The incentives are not hidden.

What women actually experienced

Here is where this piece has to be careful, because dismissing the phrase would be as wrong as amplifying it.

The accounts underneath the phrase are real, and they are public. They are Reddit posts, which is where this drug's side conversations mostly live. In a published analysis of 660 posts from r/WegovyWeightLoss, the psychosocial impact of weight loss was the second-largest theme in the entire corpus, behind only whether the drug worked⁵.

The post that did most to launch the term came from r/Ozempic and is quoted in Healthline's August 2025 report on it. A woman who had lost 20kg and had no noticeable sagging skin on her stomach, arms or legs had gone to her gynecologist about pain when cycling and sitting for long periods: "Turns out I've lost all my fat pads in my vulva! She told me my vulva is saggy and I will continue to experience pain when biking/sitting."⁶ That is not hysteria. That is a woman describing a body that has changed shape, and repeating what a clinician told her about it.

There are also perfectly ordinary explanations available. Losing a great deal of weight quickly changes tissue everywhere; the face changed visibly, and there was never a reason to think the vulva was exempt. Low estrogen produces exactly this constellation — the condition clinicians call genitourinary syndrome of menopause, whose two most common symptoms in the international consensus definition are vaginal dryness and painful sex³, and which for a woman in her forties may simply have arrived in the same year as her prescription. Sexual function after major weight loss has been studied properly in bariatric patients, and it runs opposite to the panic: pooled across 16 studies and 953 women, scores improved in every domain except pain⁴.

And the thing nobody put in a headline: no study has ever measured the thing the phrase describes. Nobody has looked at vulvar tissue, dryness or sensation on a GLP-1, inside a trial or outside one. The nearest evidence is a phenome-wide analysis of 17,267 adults with type 2 diabetes in the All of Us program, published in May 2026, which screened 974 diagnoses following a prescription — and did include vulvovaginal ones. Set against an SGLT2 inhibitor, semaglutide came out lower: candidiasis of the vulva and vagina at a per-protocol hazard ratio of 0.31, with a confidence interval of 0.17 to 0.55⁷. That is a comparison with a drug class notorious for genital infections rather than proof of safety, and infection was never what the phrase was about. But it is the only large dataset anyone has aimed at this part of the body, and it does not point where the panic did.

The cost of a name

A phrase like this does three things at once.

It gives women language for something they were experiencing and had no word for, which is genuinely valuable and is why it spread.

It attributes that experience to a specific cause, on no evidence, which sends people to the wrong conversation — worrying about a medication rather than asking about estrogen, or an infection, or the SGLT2 inhibitor also in the cabinet.

And it makes the subject embarrassing, because a body part plus a drug name is a joke format. Women who might have raised dryness with a clinician now had to raise "Ozempic vulva" instead.

That silence is older than the phrase, and it has been measured. In the Women's EMPOWER survey of 1,858 American women aged 45 and over with vulvar and vaginal atrophy symptoms, 72% of those who had never used any treatment had never discussed their symptoms with a health professional at all — most often because they took the symptoms for a natural part of aging, something to live with. Where the conversation did happen, the woman started it 85% of the time⁸. A punchline for a name is not what makes that conversation easier to start.

The searches have collapsed. The symptoms have not. That gap is the actual story, and it is the reason we are writing about a term six months after it stopped trending.

What is worth doing

Dryness and irritation are treatable, and treatable regardless of what caused them — moisturizers, lubricants, and where appropriate local estrogen are established options. Itching, unusual discharge or odor points toward infection, which is tested rather than assumed. And anything arriving alongside hot flashes or cycle changes is a perimenopause conversation wearing someone else's name.

This page is about the phrase rather than the symptom, which was the point of writing it. If you came here because something is actually wrong — dryness, thrush or bacterial vaginosis, or bleeding that is not a period — the symptom-by-symptom version, with the treatment evidence and the one sign never to wait out, is here.

None of that requires knowing whether the drug did it. A named, board-certified clinician makes a sensitive symptom easier to raise — The Virtual NP is run by a named nurse practitioner, Sandra Jordan, MSN, APRN, FNP-C, rather than an anonymous intake form.

More in this territory: the body you are now in, "Ozempic face" explained, and what a GLP-1 does to a marriage.